Journal article

The role of genetic breast cancer susceptibility variants as prognostic factors

Peter A Fasching, Paul DP Pharoah, Angela Cox, Heli Nevanlinna, Stig E Bojesen, Thomas Karn, Annegien Broeks, Flora E van Leeuwen, Laura J van 't Veer, Renate Udo, Alison M Dunning, Dario Greco, Kristiina Aittomaki, Carl Blomqvist, Mitul Shah, Borge G Nordestgaard, Henrik Flyger, John L Hopper, Melissa C Southey, Carmel Apicella Show all

Human Molecular Genetics | OXFORD UNIV PRESS | Published : 2012


Awarded by European Community

Awarded by CR-UK

Awarded by European Union COST programme

Awarded by Cancer Research UK

Awarded by Dutch Cancer Society

Awarded by National Institutes of Health (NIH) National Cancer Institute (NCI)

Awarded by NCI Recovery Act grant

Awarded by NCI Specialized Program of Research Excellence (SPORE) in breast cancer

Awarded by Deutsche Krebshilfe e. V.

Awarded by state of Baden-Wurttemberg through the Medical Faculty of the University of Ulm

Awarded by Associazione Italiana per la Ricerca sul Cancro

Awarded by 'Stichting tegen Kanker'

Awarded by Breast Cancer Campaign

Awarded by Yorkshire Cancer Research

Awarded by Academy of Finland

Awarded by Fondo de Investigacion Sanitario

Awarded by United States National Cancer Institute, National Institutes of Health (NIH)

Awarded by The Francis Crick Institute


Funding Acknowledgements

This work was supported by funding from the European Community's Seventh Framework Programme under grant agreement - 223175 (HEALTH-F2-2009-223175) (COGS). Co-ordination and genotyping in BCAC was funded by CR-UK (C1287/A10118 and C1287/A12014). Meetings of the BCAC have been funded by the European Union COST programme (BM0606). D. F. E. is a Principal Research Fellow of CR-UK. The genotyping was supported by Cancer Research UK (C490/A10124) and (C1287/A12014). Funding of the constituent studies and data analysis was supported by the Cambridge Biomedical Research Centre, Cancer Research UK (C490/A10119). Other studies have been funded by the Dutch Cancer Society (grants NKI 2001-2423; NKI 2007-3839), the Dutch National Genomics Initiative, the Dutch Biobanking and Biomolecular Resources Research Infrastructure, the National Institutes of Health (NIH) National Cancer Institute (NCI) grant CA122340, NCI Recovery Act grant CA122340Z, NCI Specialized Program of Research Excellence (SPORE) in breast cancer CA116201, the ELAN research program, University Hospital Erlangen, the Deutsche Krebshilfe e. V. (70492), the state of Baden-Wurttemberg through the Medical Faculty of the University of Ulm (P.685), the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, the Associazione Italiana per la Ricerca sul Cancro (4017) and funds from Italian citizens who allocated the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects "5x1000"), the 'Stichting tegen Kanker' (232-2008 and 196-2010), the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, the Academy of Finland and by the strategic funding of the University of Eastern Finland, the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council and Copenhagen University Hospital, Herlev Hospital, Rudolf Bartling Foundation, the National Breast Cancer Foundation of Australia, Cancer Australia, the National Health and Medical Research Council of Australia, the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, the Cancer Foundation of Western Australia, the Victorian Health Promotion Foundation (Australia), the Breast Cancer Campaign (2004Nov49), Yorkshire Cancer Research (S295, S299 and core funding), the Dietmar-Hopp Foundation, the Helmholtz Society, the German Cancer Research Center (DKFZ), the Finnish Cancer Foundation, the Academy of Finland, the University of Oulu, the Oulu University Hospital, Biocenter Oulu; the Helsinki University Central Hospital Research Fund, Academy of Finland (132473), the Finnish Cancer Society, the Nordic Cancer Union and the Sigrid Juselius Foundation; the Dutch Cancer Society, grants DDHK 2004-3124 and DDHK 2009-4318, the Swedish Cancer Society, the Stockholm Cancer Society, the Gustav V Jubilee foundation, the Bert von Kantzow foundation, the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH), the Susan G. Komen Breast Cancer Foundation and Marit and Hans Rausings Initiative Against Breast Cancer, the Genome Spain Foundation, the Red Tematica de Investigacion Cooperativa en Cancer and grants from the Asociacion Espanola Contra el Cancer and the Fondo de Investigacion Sanitario (PI081583 and PI081120).The ABCFS, NC-BCFR and OFBCR work was supported by the United States National Cancer Institute, National Institutes of Health (NIH) under RFA-CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Cancer Prevention Institute of California (U01 CA69417) and University of Melbourne (U01 CA69638). Samples from the NC-BCFR were processed and distributed by the Coriell Institute for Medical Research. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government or the BCFR.